EU Parliament refuses to accept EMA accounts

Published: 30-Apr-2012
Finance

MEPs request action plan to improve procurement and contract management


The European Parliament’s budgetary control committee has refused to approve the latest accounts of the European Medicines Agency (EMA), pending further inquiries.

MEPs have requested an action plan to improve procurement and contract management and sought assurances about the impartiality of EMA’s employees and external advisors.

MEPs also criticised EMA’s management board refusing to establish a new payment system.

See more

You may also like

Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Read more
Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Building a beta-lactam powerhouse: Gaelic’s strategic leap with Athlone In December 2025, Gaelic Laboratories, a world-class manufacturer of beta-lactam (penicillin) products, acquired Athlone Laboratories, another leading developer and supplier of oral dose beta-lactams
  2. Symbiosis begins commercial manufacturing at new FDA-inspected facility Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
  3. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland
  4. £12 million in grants to tackle superbugs in a global context The researchers will use a range of approaches, from clinical and microbiological to geography, modelling and social sciences, to identify, prioritise and understand the specific problem of AMR across different communities and environments in Kenya, Tanzania, Uganda, Malawi and Thailand
  5. ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies

Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Finance

EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups

The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance

Fresh capital flows into neurodegeneration, cancer and vascular-access developers

A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access
Finance

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget
Subscribe now